0000899243-20-002292.txt : 20200129 0000899243-20-002292.hdr.sgml : 20200129 20200129164751 ACCESSION NUMBER: 0000899243-20-002292 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200127 FILED AS OF DATE: 20200129 DATE AS OF CHANGE: 20200129 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lehrer-Graiwer Joshua CENTRAL INDEX KEY: 0001789673 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 20558816 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC. STREET 2: 171 OYSTER POINT BLVD., SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 171 OYSTER POINT BLVD, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 171 OYSTER POINT BLVD, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-27 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001789673 Lehrer-Graiwer Joshua C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Medical Officer Common Stock 2020-01-27 4 M 0 781 27.90 A 2797 D Common Stock 2020-01-27 4 S 0 781 71.15 D 2016 D Stock Option (Right to Buy) 27.90 2020-01-27 4 M 0 781 0.00 D 2027-07-25 Common Stock 781 4688 D This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from July 26, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. /s/Lesley Ann Calhoun, as Attorney-in-Fact 2020-01-29